Pharmaceuticals and Healthcare Reports 5EU Melanoma Market

5EU Melanoma Market Trends, Outlook and
Overview Report 2023
“The market will increase by four-fold over the
forecast period, reaching $5.64 billion in 2023 at a
CAGR of 15.5%.”
Summary
Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for
melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. Radiant
Insights estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM
covered in this report. The market will increase by four-fold over the forecast period, reaching
$5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma
incident cases as well as the approval and uptake of premium-priced products, such as PD-1-
targeting mAbs and BRAF/MEK inhibitor combinations. Radiant Insights expects, by the end of the
forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market
(including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share
of the melanoma market.
Read Complete Report with TOC @
http://www.radiantinsights.com/research/melanoma-5eu-drug-forecast-and-market-
analysis-to-2023
Radiant Insights forecasts the melanoma market in the 5EU to increase from $373m in 2013. The
melanoma branded market in the 5EU in the base year was small because there were only three
approved brands, Yervoy, Zelboraf, and Tafinlar, and Tafinlar was only approved in Q4 2013. The
Follow Us: